Lineage Cell Therapeutics Interim Filing: Quarterly Net Result Flips to Profit While Year-to-Date Window Stays in Loss

Bottom line

- The headline takeaway from this filing is that Lineage Cell Therapeutics, Inc. (LCTX) reported positive top-line results alongside mixed bottom-line signals across both interim windows covered in the document. The three-month reporting period finished in net income, while the six-month year-to-date window remained in a loss, and the diluted earnings-per-share line stayed negative in both windows, leaving the bottom-line picture more nuanced than the revenue trend alone would suggest.

- This conclusion is grounded in the following reported figures, all of which appear in the statement that the machine inserts after this draft. Revenue from Contract with Customer, Excluding Assessed Tax registered a positive value in both the three months ended June 30, 2026 and the six months ended June 30, 2026, with the same revenue line also registering positive in the three months ended June 30, 2025 and the six months ended June 30, 2025. A second revenue caption labelled Revenues likewise printed a positive value in the three months ended June 30, 2026, the six months ended June 30, 2026, the three months ended June 30, 2025 and the six months ended June 30, 2025.

- Net Income (Loss) Attributable to Parent was a profit in the three months ended June 30, 2026, against a loss in the three months ended June 30, 2025, while the year-to-date the six months ended June 30, 2026 figure remained a loss, smaller than the prior-year the six months ended June 30, 2025 loss. Earnings Per Share, Diluted was a loss in the three months ended June 30, 2026 and a loss in the three months ended June 30, 2025, and similarly a loss in the six months ended June 30, 2026 and a loss in the six months ended June 30, 2025.

Operating Income (Loss) was a loss in the three months ended June 30, 2026, a loss in the three months ended June 30, 2025, a loss in the six months ended June 30, 2026 and a loss in the six months ended June 30, 2025, framing a still-loss-making operating backdrop even as the headline turned positive on a quarterly basis. - In terms of authorized year-over-year movement, Revenue from Contract with Customer, Excluding Assessed Tax was lower in the three months ended June 30, 2026 than in the three months ended June 30, 2025 and lower in the six months ended June 30, 2026 than in the six months ended June 30, 2025.

Revenues showed the same pattern in both windows. Net Income (Loss) Attributable to Parent was higher in the three months ended June 30, 2026 than in the three months ended June 30, 2025, moving from a loss to a profit, and higher in the six months ended June 30, 2026 than in the six months ended June 30, 2025, while remaining a loss in both periods. Earnings Per Share, Diluted was higher in both windows, with both periods continuing to register a loss.

Operating Income (Loss) was higher in both windows, again remaining a loss in each. - The source scope is the interim filing identified by 10-Q for period-ended-2026-06-30, filed under accession 0001193125-26-338064 for CIK 0000876343. The quoted evidence draws from the Special Note Regarding Forward-Looking Statements and the condensed consolidated interim financial statements section, supported by references Item 1, Item 1A, Item 2, Item 3, Item 4, Item 5, Item 6, Item 8, Note 2, Note 4, Note 6 and Note 13, and no peer or industry comparison is included in the filing evidence The filing evidence contains no peer or industry comparison..

- The filing evidence does not attribute this change to any single cause.

Financial performance

- Revenue from Contract with Customer, Excluding Assessed Tax was $1,069,000 USD for the three months ended June 30, 2026 and was $2,765,000 USD for the three months ended June 30, 2025; the prior-period figure was higher, and the reported comparison records a year-over-year decrease with the current and prior periods both reported on a positive basis. - The separate Revenues line was $1,069,000 USD for the three-month period and $2,765,000 USD for the prior-year three-month period; on that parallel measure the current period is lower than the prior period, again with both periods positive.

- For the year-to-date window, Revenue from Contract with Customer, Excluding Assessed Tax was $2,794,000 USD for the six months ended June 30, 2026 versus $4,267,000 USD for the six months ended June 30, 2025, and Revenues was $2,794,000 USD versus $4,267,000 USD; across both label sets the half-year current period is lower than the prior-year half-year period. - Operating Income (Loss) was -$8,923,000 USD for the three-month period versus -$19,780,000 USD for the prior-year three-month period; both periods are losses, and the reported comparison records a year-over-year increase from a loss to a loss.

The filing evidence does not attribute this change to any single cause. - Operating Income (Loss) was -$16,516,000 USD for the year-to-date period versus -$26,285,000 USD for the prior-year half-year period; both periods are losses, with the current-period loss larger in absolute terms and the authorized comparison marking an increase from loss to loss. The filing evidence does not attribute this change to any single cause.

- Net Income (Loss) Attributable to Parent was $1,482,000 USD for the three-month period versus -$30,464,000 USD for the prior-year three-month period; the current period is positive and the prior period is negative, and the authorized comparison records the year-over-year transition from loss to profit. The filing evidence does not attribute this change to any single cause. - Net Income (Loss) Attributable to Parent was -$3,330,000 USD for the year-to-date period versus -$34,603,000 USD for the prior-year half-year period; the current and prior periods are both losses, and the authorized comparison records an increase from loss to loss.

The filing evidence does not attribute this change to any single cause. 13 per diluted share USD/SHARES for the prior-year three-month period; the reported comparison marks an increase, with the current and prior periods both losses. 15 per diluted share USD/SHARES for the prior-year half-year period; again both periods are losses with an authorized increase.

- The accompanying notes state that no changes have been made to the company's significant accounting policies, with the discussion of policies delivered in Item 8 and the cross-reference to note-level disclosures captured in Note 2. - Additional capital-requirements commentary appears in Note 4, and total operating expenses are aggregated by line-item alongside the related expense notes covered in Note 6 and the shareholders' equity disclosures in Note 13. - On a quarter-versus-quarter basis, the revenue lines move lower against the prior-year same quarter while the three-month operating loss narrowed and the three-month net result moved from a prior-year loss to a current-quarter profit, leaving loss-per-share still negative for both quarters.

- The year-to-date window shows a uniform directional split: both revenue measures are lower than the prior-year half-year period while the operating loss, net loss, and diluted loss per share are all measured as larger losses than the prior-year half-year period. The filing evidence contains no peer or industry comparison. The filing evidence does not disclose segment-level detail for this dimension.

Operating drivers and segments

- The filing describes the business as a single operating and reportable segment at the consolidated level, with the chief operating decision maker using consolidated net loss as the measure of segment profit or loss, allocating resources and assessing performance on that same consolidated basis; other segment items reflected in the condensed consolidated statements of operations include interest income, gain or loss on marketable equity securities, change in fair value of warrant liability, foreign currency transaction gain, other income or expense, and any provision for income tax benefit when applicable. - Revenue from Contract with Customer, Excluding Assessed Tax and the separately reported Revenues line are both shown for the three-month and six-month year-to-date windows of the current period and the prior-year comparative period, with all four current-period values lower than their prior-year counterparts and both full-period and quarterly Revenues again moving lower against the prior year; the Authorized Comparisons table for both Revenue from Contract with Customer, Excluding Assessed Tax and Revenues records a direction of decrease for the half-year-over-half-year and quarter-over-quarter relationships. - Operating Income (Loss) is reported as a loss in all four windows, both the prior-year comparative for the three-month and six-month periods and the current three-month and six-month periods, with each current-period loss narrower than the prior-year loss, consistent with the Authorized Comparisons table direction of increase on a loss-to-loss transition. - Because the company reports as one segment with consolidated net loss as the profit measure, no segment-level margin decomposition is disclosed in the filing; analysts working with this single-segment presentation cannot break out business-line margin contribution beyond what is shown in the condensed consolidated statements of operations and the referenced note on operating expenses.

- Management frames forward-looking discussion around the potential to receive developmental, regulatory, and commercialization milestone and royalty payments under the Collaboration and License Agreement with F. Hoffmann-La Roche Ltd and Genentech, Inc.; plans to research, develop, and commercialize product candidates; the initiation, progress, success, cost, and timing of clinical trials and other product development activities; the therapeutic potential of the product candidates and the indications the company intends to pursue; the AlloSCOPE platform and the company's ability to manufacture product candidates for clinical development and, if approved, commercialization, along with the timing and costs of such manufacture; the timing and likelihood of regulatory filings and approvals; the potential of the cell therapy platform more broadly; the ability to obtain additional capital; the potential that holders of outstanding warrants will exercise on a cash basis; existing and potential future collaborations with pharmaceutical and biotechnology companies, government agencies, academic laboratories, and research institutes for the discovery, development, and commercialization of novel cell therapy products; the size and growth of potential markets and the company's ability to serve them; the scope and value of intellectual property rights; and the effects of the cited Iran War, the ongoing Israeli regional conflict, and broader geopolitical conflicts, political and economic instability, public health emergencies, and macroeconomic conditions on operations, workforce, and clinical trials, including those involving OpRegen. - No management explanation in the filing attributes the current-period revenue or operating-loss changes to any single cause, and the standard forward-looking cautionary language applies to all of the foregoing statements.

Cash flow and capital

For Lineage Cell Therapeutics, Inc. (LCTX), filed as 10-Q for period-ended-2026-06-30 under accession 0001193125-26-338064, the cash flow statement for the six-month year-to-date window covers two comparative periods, while the balance sheet is presented at a single point in time.

Reported facts - Cash and Cash Equivalents, at Carrying Value stood at $37,355,000 as of the balance sheet date of June 30, 2026, the most recent balance sheet date. This is the headline liquidity figure investors typically read first, and management's own going-concern language in the filing is anchored to this balance together with marketable securities. - Accounts Payable, Current was $1,536,000 as of the balance sheet date of June 30, 2026, and Accounts Payable and Accrued Liabilities, Current was $5,387,000 as of the balance sheet date of June 30, 2026. The two line items are shown separately in the condensed consolidated balance sheet, and the accrued line sits above the bare payables figure, implying accruals and other short-term obligations are the larger component. - Net Cash Provided by (Used in) Financing Activities was $4,737,000 in the six months ended June 30, 2025 and $10,027,000 in the six months ended June 30, 2026, an authorized year-over-year increase from a positive prior-period base to a higher positive current-period figure. - Net Cash Provided by (Used in) Investing Activities was $1,889,000 in the six months ended June 30, 2025 and $1,634,000 in the six months ended June 30, 2026, an authorized year-over-year decrease, with the current six-month window still positive. - Net Cash Provided by (Used in) Operating Activities was -$10,425,000 in the six months ended June 30, 2025 and -$15,322,000 in the six months ended June 30, 2026, an authorized year-over-year decrease, with both periods showing a negative figure that is larger in magnitude in the current window. - Payments to Acquire Property, Plant, and Equipment were $111,000 in the six months ended June 30, 2025 and $163,000 in the six months ended June 30, 2026, an authorized year-over-year increase on a positive base.

Management explanations Management notes in the Capital Resources and Additional Capital Requirements discussion that, since inception, the company has funded operations primarily through equity issuance, proceeds from former subsidiary stock sales, research grants, collaboration revenue, royalties, and research products and services. The same commentary states management's view that cash, cash equivalents, and marketable securities as of the issuance date will be sufficient to carry out planned operations for at least twelve months from issuance. Licensing obligations and Israel Innovation Authority grants are described as creating future payment commitments such as sublicense fees, milestone payments, redemption fees, royalties, and patent maintenance fees, including amounts tied to the worldwide collaboration with Roche.

Analyst inference Operating cash burn widened on a year-over-year basis while investing cash flow remained positive and financing cash flow moved higher, a pattern consistent with management leaning on capital markets while still receiving positive investing-period cash inflows, which the filing attributes in part to marketable securities activity. Capital expenditure rose, but stays a small absolute line within the broader cash picture.

Counter-evidence and unknowns The filing does not break out marketable securities balances in this section's catalog, so a cash-plus-securities runway view cannot be reconstructed from the supplied facts. The underlying drivers of the wider operating cash outflow and the higher financing inflow are not separately disclosed at this level of detail. The filing evidence does not attribute this change to any single cause.. No peer or industry cash-flow comparison is provided, so cross-company benchmarking on burn or capex intensity is not supported here. The filing evidence contains no peer or industry comparison..

Peer and historical context

- The filing supplies two parallel historical frames — the three-month reporting period and the six-month year-to-date period — and each carries both a "Revenue from Contract with Customer" line and a separate "Revenues" line. Stating both side by side lets the reader see the consolidated contract revenue alongside the broader revenue category that the chief operating decision maker actually reviews, which is material because management explicitly says in the narrative that the CODM function looks only at revenue and functional expenses at the consolidated level. - The most striking year-over-year pivot inside this filing is the swing in Net Income (Loss) Attributable to Parent for the three-month reporting period, which moved from a loss in the prior-year comparative to a profit in the current quarter, while the year-to-date half-year remains a loss in both periods. That asymmetry between the quarter and the half-year is the single sharpest change in the historical record this section can lean on. - The historical cash-flow story is uniform in sign but split in direction. Net Cash Provided by (Used in) Operating Activities is negative in both year-to-date periods and the current year-to-date period is authorized as a decrease relative to the prior year, so the cash burn from operations widened on a year-over-year basis even as the headline net result improved for the quarter. Operating Income (Loss) is negative in all four cells (both periods in both years) and is authorized as an increase in both comparisons, so the operating loss narrowed in the quarter and in the half-year even though it never crossed into operating profit.

- Revenue from Contract with Customer, Excluding Assessed Tax, and the separate Revenues line, are both authorized to have decreased in the half-year and in the quarter relative to their prior-year comparatives, which is the opposite direction of the net income pivot. A reader looking only at the top line would see a top-line contraction while a reader looking only at the bottom line of the quarter would see a swing to profit, and the filing does not bridge that gap on a causal basis. - Payments to Acquire Property, Plant, and Equipment for the half-year are authorized as an increase versus the prior-year comparative, and Net Cash Provided by (Used in) Investing Activities is authorized as a decrease year over year. Capital spending therefore rose while net investing cash flow still fell, an inconsistency the historical record does not resolve inside the quoted evidence. - The historical record contains no peer or industry data inside this filing, so any cross-company benchmarking would have to be sourced from outside the document. - The filing evidence does not attribute the revenue contraction, the operating-loss narrowing, or the quarter's net-income swing to any single cause.

The filing evidence does not attribute this change to any single cause. The filing evidence contains no peer or industry comparison.

Scenario analysis

- The reported top line for both windows sits below the prior-year comparative on a reported basis for $2,765,000 versus $1,069,000 and for $4,267,000 versus $2,794,000, leaving the firm's collaboration-based revenue stream on a lower glide path entering the back half of the year. - Net result for the three-month reporting period has returned to a profit, with -$30,464,000 versus $1,482,000 transitioning from a loss to a profit, while the six-month window remains in a loss position though narrower than the -$34,603,000 loss that was recorded against -$3,330,000. - Cost-related accruals and contingent obligations remain linked to external milestone events and the timing of royalties that could flow under the worldwide collaboration with the Roche entity, leaving operating outcomes structurally tethered to externally driven triggers rather than to recurring contract volume. - Reported as: Revenues of $1,069,000 for the three-month reporting period against $2,765,000 for the prior-year comparative, and Revenues of $2,794,000 for the six-month year-to-date period against $4,267,000 for the prior-year comparative. - Status: reported; outcome direction authorized as a decrease for the Revenue line and an increase for the Net result line, with the period transitions permitted by the catalog rules.

- The earlier net loss that characterised -$3,330,000 and -$30,464,000 narrows substantially on the back of progress against contracted performance obligations under the agreements with the Roche entity and WDI, with collaboration revenue running through the input method reflecting an improving cost-to-completion ratio. - Reported Revenues of $1,069,000 outpaces the $2,765,000 comparative, and the six-month Revenues of $2,794,000 exceeds the $4,267,000 comparative, supported by sustained milestone delivery and a smoother royalty stream under the worldwide collaboration with the Roche entity. - The transition flagged in the base view, from a loss against -$30,464,000 to a profit on $1,482,000, extends into a clean full-year profit profile. - Contingent payment obligations tied to sublicense events and milestones under the worldwide collaboration with the Roche entity crystallise on schedule, supplying predictable royalty receipts without forcing compensating expense. - Status: conditional; depends on externally driven milestones, regulatory clearances, and royalty triggers that sit outside the issuer's unilateral control.

- The revenue softness implied by $2,765,000 versus $1,069,000 and by $4,267,000 versus $2,794,000 deepens, with Revenues of $1,069,000 and $2,794,000 falling further below their $2,765,000 and $4,267,000 comparatives. - The narrower half-year loss reported for -$3,330,000 relative to -$34,603,000 re-widens as cost-to-completion revisions push recognised collaboration revenue lower on the input method, even though the three-month profit result on $1,482,000 versus -$30,464,000 is preserved for now. - Payment obligations tied to licensor milestones, IIA redemption fees, and patent maintenance accruals accelerate ahead of incoming royalties, widening the contingent-payment schedule referenced in the filing without any certainty on the timing of matching receipts. - Conclusion: The filing evidence does not attribute this change to any single cause. - Comparison context: The filing evidence contains no peer or industry comparison. - Reviewers weighing these scenarios can size the underlying revenue shifts with ROI Calculator while keeping in mind that the catalog permits only the comparative directions shown above.

Risks and what to watch

- Reported facts: - Net Income (Loss) Attributable to Parent for the six-month year-to-date period was a loss of -$3,330,000 USD, against a prior-year six-month loss of -$34,603,000 USD, leaving the cumulative picture in negative territory. - Net Income (Loss) Attributable to Parent for the three-month reporting period was a profit of $1,482,000 USD, against a prior-year three-month loss of -$30,464,000 USD, registering a single-quarter swing from loss to profit. - Revenue from Contract with Customer, Excluding Assessed Tax was $2,794,000 USD for the six-month year-to-date period versus $4,267,000 USD in the prior-year six-month comparative, and $1,069,000 USD for the three-month period versus $2,765,000 USD in the prior-year three-month comparative.

- The reconciling Revenues caption printed $2,794,000 USD for the six-month year-to-date period against $4,267,000 USD prior-year six-month, and $1,069,000 USD for the three-month period against $2,765,000 USD prior-year three-month. - Management explanations: - Management attributes revenue recognition to the cited revenue-from-contracts standard, applying the input method against total estimated collaboration costs, and states that revisions to those cost estimates are recorded on a cumulative basis through revenue and deferred revenue.

- Management flags additional capital requirements alongside the marketable-securities discussion, indicating that continued losses may pressure liquidity. - Management states no significant accounting policy changes during the six-month year-to-date period and identifies a new expense-disaggregation standard not yet adopted. - Analyst inference: - The single-quarter transition from loss to profit is not corroborated by the six-month cumulative line, which remains a loss, raising questions about the durability of the quarterly result.

- Both revenue captions contract year over year in both windows, suggesting the underlying collaboration stream, including the cited Roche and WDI arrangements, is delivering less recognized revenue even as the quarter flips to profit. - Because cumulative cost-estimate revisions flow through revenue, the next quarter could show a sharp swing without any change in underlying scientific activity. - Counter-evidence: - The contract-with-customer decline in both periods cuts against the loss-to-profit narrative for the quarter, since lower recognized revenue would not mechanically produce a swing to profit absent an offsetting cost or non-operating item.

- The prior-year six-month loss of -$34,603,000 USD provides a reference base that the current six-month loss of -$3,330,000 USD has not improved past, which tempers optimism on the quarterly profit print. - Unknowns: - Whether the quarterly loss-to-profit transition persists into the next reporting window. - The size and direction of any cumulative catch-up adjustment from revised total estimated collaboration costs that will land in the next reported window.

- Whether management will pursue an equity-linked capital raise to fund continuing operating losses, and how any such raise would interact with the preferred-share authorization referenced in the shareholders' equity note. - The eventual income-statement mix impact of the new expense-disaggregation standard on cost of royalties, SG&A, and research and development disclosure. - Metrics to watch next period: - Whether the loss-to-profit transition persists or reverses into a loss.

- Direction of contract-with-customer revenue and the reconciling Revenues line in both the quarter and year-to-date windows. - Any cumulative-effect adjustment disclosed as a change in estimated collaboration costs. - Capital-raise activity tied to additional capital requirements, including any issuance under the preferred-share authorization described in the shareholders' equity note.

- Initial disclosures, if any, about the new expense-disaggregation standard as the effective date approaches. - The filing evidence does not attribute this change to any single cause. - The filing evidence contains no peer or industry comparison.

- Readers modeling the burn-rate-versus-revenue trade-off can frame the directional read with the ROI Calculator, and for broader context on interim profit recoveries, the related ATN International returns to interim profitability on stronger revenue across both reporting windows insight offers a useful comparison point.